STRATA Skin Sciences has secured approval from Japan’s Ministry of Health, Labor and Welfare for its XTRAC Momentum 1.0 device.

The next-generation excimer laser system is designed to allow for the precise delivery of targeted UVB light therapy to treat specific skin areas.

It is intended for both adult and paediatric patients suffering from inflammatory skin conditions.

Initially launched in the US in early 2022, the XTRAC Momentum 1.0 device will now be available in Japan through JMEC, Strata's long-term strategic partner and distributor.

Strata president and CEO Dr Dolev Rafaeli said: “With this regulatory approval, we are now able to offer the Momentum device - our most advanced excimer laser - into the Japanese dermatology market.

“Working with JMEC, we look forward to introducing doctors and patients to the benefits of Momentum for the treatment of various dermatology conditions, such as psoriasis, eczema, and vitiligo.”

STRATA's excimer devices are already in use by more than 300 hospitals and dermatology clinics across Japan.

The new XTRAC Momentum 1.0 offers advancements with higher power and a faster repetition rate compared to existing models.

Strata said its new device is the latest addition to its excimer laser technology.

Additionally, the XTRAC Momentum 1.0 device provides a new user interface and slim design to enhance the treatment experience.

Strata Skin Sciences is a medical technology company focused on developing, commercialising, and marketing products for treating dermatologic conditions.

The company offers products such as the XTRAC excimer laser, the TheraClearX Acne Therapy System and the VTRAC lamp systems.